Literature DB >> 33205233

Risk factors for tumor recurrence and progression of spindle cell oncocytoma of the pituitary gland: a systematic review and pooled analysis.

Huy Gia Vuong1,2, Truong Phan Xuan Nguyen3, Nguyen Pham4, Ian F Dunn5.   

Abstract

INTRODUCTION: Spindle cell oncocytoma (SCO) is an extremely rare sellar neoplasm. No observational studies have been reported so far to investigate the prognostic factors of this tumor entity. This systematic review aimed to elucidate the risk factors for tumor recurrence/progression of SCO.
METHODS: We searched for relevant articles in PubMed and Web of Science. Studies providing individual patient data with follow-up information of SCO cases were included. Pearson's Chi square and Fisher's exact test were used for categorical variables while t test or Mann-Whitney tests were applied for continuous variables, if applicable. We used the Cox regression model to assess the effects of suspected variables on progression-free survival (PFS).
RESULTS: A total of 38 case reports and case series comprising of 67 SCOs were included for final analyses. Recurrent/progressive tumors were noted in 38.8% of cases. Among the clinicopathological factors, only the extent of surgery was a significant risk factor for tumor recurrence/progression. SCO patients with a subtotal resection had a significantly higher risk for tumor relapse in comparison with complete removal (HR 7.51; 95% CI 1.75-32.31; p = 0.007).
CONCLUSION: Our study demonstrated the characteristic clinicopathological features of SCOs with a high recurrence/progression rate and outlined the predictor for tumor relapse. Failure to achieve gross total resection is the only risk factor for tumor recurrence/progression.

Entities:  

Keywords:  Adenohypophysis; Neurohypophysis; Pituitary; Progression; Recurrence; Spindle cell oncocytoma

Mesh:

Year:  2020        PMID: 33205233     DOI: 10.1007/s11102-020-01110-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  45 in total

Review 1.  Pituitary Medicine From Discovery to Patient-Focused Outcomes.

Authors:  Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2016-02-23       Impact factor: 5.958

Review 2.  Essential role of ultrastructural examination for spindle cell oncocytoma: Case report of a rare neoplasm and review of the literature.

Authors:  Elia Guadagno; Mariarosaria Cervasio; Alberto Di Somma; Marialuisa Califano; Domenico Solari; Marialaura Del Basso De Caro
Journal:  Ultrastruct Pathol       Date:  2016       Impact factor: 1.094

3.  Immunoprofiling of glial tumours of the neurohypophysis suggests a common pituicytic origin of neoplastic cells.

Authors:  Christian Hagel; Rolf Buslei; Michael Buchfelder; Rudolf Fahlbusch; Markus Bergmann; Armin Giese; Jörg Flitsch; Dieter K Lüdecke; Markus Glatzel; Wolfgang Saeger
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

Review 4.  Pituitary-Tumor Endocrinopathies.

Authors:  Shlomo Melmed
Journal:  N Engl J Med       Date:  2020-03-05       Impact factor: 91.245

5.  Rapidly recurring folliculostellate cell tumor of the adenohypophysis with the morphology of a spindle cell oncocytoma: case report with electron microscopic studies.

Authors:  C I Coiré; E Horvath; H S Smyth; K Kovacs
Journal:  Clin Neuropathol       Date:  2009 Jul-Aug       Impact factor: 1.368

6.  Neuron precursor features of spindle cell oncocytoma of adenohypophysis.

Authors:  Sanda Alexandrescu; Robert E Brown; Nitin Tandon; Meenakshi B Bhattacharjee
Journal:  Ann Clin Lab Sci       Date:  2012       Impact factor: 1.256

Review 7.  Spindle cell oncocytoma of adenohypophysis: Report of a case and immunohistochemical review of literature.

Authors:  Huy Gia Vuong; Tetsuo Kondo; Thong Minh Tran; Naoki Oishi; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Wang Jieying; Ryohei Katoh
Journal:  Pathol Res Pract       Date:  2015-09-08       Impact factor: 3.250

8.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

Review 9.  Diagnosis and Treatment of Pituitary Adenomas: A Review.

Authors:  Mark E Molitch
Journal:  JAMA       Date:  2017-02-07       Impact factor: 56.272

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

View more
  3 in total

1.  Recommendation to improve the WHO classification of posterior pituitary tumors as a unique entity: evidence from a large case series.

Authors:  Nidan Qiao; Haixia Cheng; Zhaoyun Zhang; Hongying Ye; Ming Shen; Xuefei Shou; Xiaoyun Cao; Hong Chen; Xiang Zhou; Yongfei Wang; Yao Zhao
Journal:  Endocr Connect       Date:  2022-06-17       Impact factor: 3.221

2.  Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence.

Authors:  Liza Das; Kim Vaiphei; Ashutosh Rai; Chirag Kamal Ahuja; Paramjeet Singh; Ishani Mohapatra; Rajesh Chhabra; Anil Bhansali; Bishan Dass Radotra; Ashley B Grossman; Márta Korbonits; Pinaki Dutta
Journal:  Endocr Connect       Date:  2021-04       Impact factor: 3.335

3.  Prediction of the Recurrence of Non-Functioning Pituitary Adenomas Using Preoperative Supra-Intra Sellar Volume and Tumor-Carotid Distance.

Authors:  Wenli Chen; Mengqi Wang; Chengbin Duan; Shun Yao; Haosen Jiao; Zongming Wang; Bin Hu; Zhigang Mao; Yonghong Zhu; Haijun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.